BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JMKX001899 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JMKX001899\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07242274-2566@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JMKX001899: Phase 3 readout est. (NCT07242274)
DESCRIPTION:JMKX001899\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or
  Metastatic KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jmkx001899#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 2274
URL:https://assetmemo.bio/drug/jmkx001899#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
